blood-brain-barrier

Migration, Crosslink

📖

blood-brain-barrier

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-blood-brain-barrier

📖 Wiki Page

general4426 wordssynced 2026-04-02

blood-brain-barrier

Blood-Brain Barrier

Introduction

Blood Brain Barrier is an important component in the neurobiology of neurodegenerative diseases. This about its structure, page provides detailed information function, and role in disease processes.

Overview

The blood-brain barrier (BBB) is a highly selective semipermeable boundary formed by brain endothelial cells, [pericytes], and astrocytic end-feet that separates circulating
blood from the brain extracellular fluid. The BBB controls the passage of molecules, ions, and cells between the blood and the central nervous system, maintaining the precisely
regulated chemical environment required for proper neuronal function. BBB dysfunction is increasingly recognized as an early and contributory event in [Alzheimer's disease],
[Parkinson's disease], [ALS], and other neurodegenerative conditions — not merely a consequence of disease[@sweeney2018].

BBB breakdown allows neurotoxic plasma proteins (fibrinogen, thrombin, albumin, immunoglobulins) to enter the brain, impairs clearance of [amyloid-beta] and other metabolic waste via the [glymphatic system], and disrupts the ionic and neurotransmitter homeostasis essential for synaptic transmission. The barrier is not merely a passive wall but an active regulatory interface that participates in brain metabolism, immune surveillance, and waste clearance.

...

blood-brain-barrier

Blood-Brain Barrier

Introduction

Blood Brain Barrier is an important component in the neurobiology of neurodegenerative diseases. This about its structure, page provides detailed information function, and role in disease processes.

Overview

The blood-brain barrier (BBB) is a highly selective semipermeable boundary formed by brain endothelial cells, [pericytes], and astrocytic end-feet that separates circulating
blood from the brain extracellular fluid. The BBB controls the passage of molecules, ions, and cells between the blood and the central nervous system, maintaining the precisely
regulated chemical environment required for proper neuronal function. BBB dysfunction is increasingly recognized as an early and contributory event in [Alzheimer's disease],
[Parkinson's disease], [ALS], and other neurodegenerative conditions — not merely a consequence of disease[@sweeney2018].

BBB breakdown allows neurotoxic plasma proteins (fibrinogen, thrombin, albumin, immunoglobulins) to enter the brain, impairs clearance of [amyloid-beta] and other metabolic waste via the [glymphatic system], and disrupts the ionic and neurotransmitter homeostasis essential for synaptic transmission. The barrier is not merely a passive wall but an active regulatory interface that participates in brain metabolism, immune surveillance, and waste clearance.

In Alzheimer disease (AD), the BBB undergoes significant structural and functional breakdown, contributing to disease progression through multiple interconnected mechanisms. This disruption represents a critical yet underappreciated component of AD pathogenesis, with emerging evidence suggesting it may be an early event rather than a secondary consequence of neurodegeneration.

Structure of the Neurovascular Unit

The BBB is a component of the broader neurovascular unit (NVU), which comprises:

Brain Endothelial Cells

The primary barrier-forming cells with unique properties distinguishing them from peripheral endothelium:

Tight junctions: Claudin-5, occludin, and ZO-1/2/3 form the paracellular barrier, restricting movement of hydrophilic molecules between cells. Claudin-5 is the most abundant — its genetic deletion increases BBB permeability to molecules < 800 Da
Minimal transcytosis: Brain endothelial cells have ~5-10x fewer caveolae (transcytotic vesicles) than peripheral endothelium, limiting bulk transcellular transport
Specialized transporters: Express glucose transporter GLUT1 (essential for brain energy supply), amino acid transporters (LAT1 for large neutral amino acids), and efflux pumps (P-glycoprotein/ABCB1, BCRP/ABCG2, MRP family)
MFSD2A: Lipid transporter (major facilitator superfamily domain-containing protein 2A) that actively suppresses caveolar transcytosis by maintaining a unique lipid composition of the endothelial membrane; essential for BBB maintenance
Receptor-mediated transcytosis (RMT): Transferrin receptor, [LRP1], and insulin receptor enable selective macromolecule transport
Low leukocyte adhesion molecules: Brain endothelial cells express minimal ICAM-1 and VCAM-1 under healthy conditions, restricting immune cell entry

Pericytes

[Pericytes] are mural cells embedded in the vascular basement membrane:

Cover 80-90% of brain capillary surface area (highest pericyte-to-endothelial ratio of any organ)
Essential for BBB formation during development and maintenance throughout adulthood
Regulate cerebral blood flow at the capillary level through contractile processes
Secrete signals (angiopoietin-1, TGF that promote tight junction expression and endothelial quiescence
Participate in [Aβ] clearance via [LRP1] and phagocytosis
Pericyte loss leads to increased non-selective transcytosis (not tight junction breakdown), causing BBB leakage[@armulik2010]
Express PDGFRβ — soluble PDGFRβ (sPDGFRβ) in CSF is a biomarker of pericyte injury

In AD, pericyte degeneration is among the earliest and most significant changes:

Mechanisms of Pericyte Loss in AD:

Amyloid-beta Toxicity: [Pericytes] are highly sensitive to [amyloid-beta] (Aβ) toxicity. In vitro studies demonstrate that Aβ exposure leads to pericyte death at concentrations found in AD brains[@bhatt2025a].

Reduced Pericyte Coverage: Post-mortem studies show a 20-30% reduction in pericyte coverage on cerebral capillaries in AD brains compared to age-matched controls[@french2025].

PDGFR-β Signaling Impairment: The platelet-derived growth factor receptor-beta (PDGFR-β) pathway, essential for pericyte recruitment and survival, shows reduced signaling in AD[@bhatt2025b].

Consequences of Pericyte Degeneration in AD:

Increased BBB Permeability: Pericyte loss leads to reduced endothelial tight junction integrity and increased transcytosis[@zlokovic2011]
Impaired Cerebral Blood Flow: [Pericytes] regulate capillary blood flow through constriction/dilation; their loss contributes to neurovascular uncoupling[@daneman2015]
Accumulation of Toxic Metabolites: Reduced pericyte-mediated clearance leads to accumulation of Aβ and other toxic proteins in the brain[@profaci2020]

Astrocytic End-Feet

[Astrocytes] extend specialized processes (end-feet) that ensheath ~99% of the abluminal vascular surface:

Express aquaporin-4 (AQP4) water channels critical for glymphatic clearance of brain metabolic waste
Release factors (sonic hedgehog, angiopoietin-1, [GDNF](/proteins/gdnf) that maintain BBB properties and induce tight junction expression
Buffer extracellular potassium and regulate neurovascular coupling (matching blood flow to neural activity)
Reactive astrogliosis in disease disrupts end-foot coverage and polarity, contributing to BBB breakdown and impaired glymphatic flow

Basement Membrane

The extracellular matrix surrounding capillaries:

Composed of collagen IV, laminin (α2, α4, α5 isoforms), fibronectin, nidogen, and heparan sulfate proteoglycans (perlecan, agrin)
Provides structural support and signaling platform for endothelial cells, pericytes, and astrocyte end-feet
Thickens and changes composition with aging and AD (increased collagen IV, decreased laminin α2)
Perivascular drainage of Aβ occurs along basement membrane pathways — termed the intramural periarterial drainage (IPAD) pathway
Basement membrane degradation by matrix metalloproteinases (MMPs) contributes to BBB breakdown in disease

BBB Transport Mechanisms

Paracellular Pathway

Tight junctions restrict paracellular movement of hydrophilic molecules:

Claudin-5: Most abundant tight junction protein in brain endothelium; selectively restricts small molecules < 800 Da
Occludin: Contributes to barrier function and tight junction stability; phosphorylation regulates its membrane localization
JAM-A/B/C: Junctional adhesion molecules that regulate tight junction assembly and leukocyte transmigration
ZO-1/2/3: Cytoplasmic scaffolding proteins linking transmembrane tight junction proteins to the actin cytoskeleton
Tight junction integrity is regulated by phosphorylation (Src, PKC), oxidative stress, and inflammatory signaling (TNF-alpha, IL-1β)

Tight Junction Disruption in AD:

| Protein | Function | Changes in AD |
|---------|----------|---------------|
| Claudin-5 | Forms paracellular seal | Downregulated at both mRNA and protein levels[@knox2022] |
| Occludin | Structural tight junction component | Reduced expression and mislocalization[@bhatt2025c] |

Mechanisms of Tight Junction Dysfunction in AD:

Oxidative Stress: Reactive oxygen species ([ROS] directly damage tight junction proteins[@bhatt2025d]

Inflammatory Cytokines: TNF-α, IL-1β, and IL-6 downregulate tight junction expression[@abbott2010]

Matrix Metalloproteinases (MMPs): MMP-2 and MMP-9 degrade tight junction proteins[@verbeek1997]

Amyloid-beta Effects: Direct Aβ binding to endothelial cells disrupts tight junction integrity[@sengillo2013]

Transcellular Pathways

| Pathway | Direction | Key Substrates | Relevance to Neurodegeneration |
|---------|-----------|---------------|-------------------------------|
| GLUT1 (SLC2A1) | Blood → brain | Glucose | Reduced in AD; causes cerebral glucose hypometabolism detectable on FDG-PET |
| LAT1 (SLC7A5) | Bidirectional | Large neutral amino acids, L-DOPA | Drug delivery route; used for PD therapy |
| P-glycoprotein (ABCB1) | Brain → blood | Aβ, drugs, xenobiotics | Reduced in AD and aging; impaired Aβ efflux and drug resistance |
| [LRP1] | Brain → blood | Aβ, [ApoE/[RAGE)](/proteins/rage) | Blood → brain | Aβ, AGEs, HMGB1 | Aβ influx receptor; upregulated 2-5× in AD; mediates Aβ re-entry into brain |
| Transferrin receptor (TfR1) | Blood → brain | Transferrin-bound iron | Therapeutic antibody shuttle target for CNS drug delivery |
| MFSD2A | Blood → brain | DHA-containing lysophospholipids | Transcytosis suppressor; downregulated with aging |

RAGE and LRP1: The Aβ Transport Dance

The receptor for advanced glycation endproducts (RAGE) and low-density lipoprotein receptor-related protein 1 (LRP1) are critical receptors that mediate Aβ transport across the BBB:

[RAGE](/proteins/rage)-Mediated Aβ Influx:

[RAGE] is a pattern recognition receptor that binds Aβ with high affinity and mediates its transport from blood to brain[@routhe2022]:

Expression Upregulation: [RAGE] expression is increased on endothelial cells in AD brains[@takano2007]
Positive Feedback Loop: Aβ-RAGE interaction creates a vicious cycle promoting more Aβ influx and inflammation[@liu2012]

[LRP1]-Mediated Aβ Efflux:

[LRP1] is a large endocytic receptor that mediates Aβ clearance from the brain[@romanitan2010]:

Efflux Function: LRP1 on brain endothelial cells binds Aβ and mediates its transport to the bloodstream[@harris2021]
Reduced Expression: LRP1 expression and function are downregulated in AD[@pun2009]
apoE4 Interaction: APOE4 (a major AD risk factor) shows reduced LRP1-mediated Aβ clearance compared to APOE3[@de1996]

The Imbalance in AD:

In healthy brains, RAGE-mediated influx and LRP1-mediated efflux are balanced. In AD, this balance is disrupted:

Increased RAGE activity → More Aβ entering the brain
Decreased LRP1 activity → Less Aβ clearing from the brain
Net Result: Progressive Aβ accumulation in the brain[@rempe2016]

A critical finding from recent research: aging causes a global shift from receptor-mediated transcytosis (selective, cargo-specific) to caveolar transcytosis (nonselective, bulk-phase):

MFSD2A (transcytosis suppressor) is downregulated with aging, allowing caveolae to form in brain endothelial cells
Increased bulk-flow transcytosis allows non-selective entry of neurotoxic plasma proteins (albumin activates [astrocytes]; fibrinogen activates [microglia]" title="Attems J, et al. The overlap between vascular and neurodegenerative pathologies in AD. Neurology. 2008;71(14:1077-1084. [DOI: 10.1212/01.wnl.0000228230.69645.f3)">40</a></sup>
CSF/serum albumin ratio: Elevated in AD, indicating global BBB leakage[@vinters1987]
CSF sPDGFRβ: Elevated soluble PDGFRβ (released from injured pericytes) correlates with BBB breakdown and cognitive decline independently of Aβ and tau][@nation2019]
Fibrinogen/IgG deposits: Detected in AD brain parenchyma by immunohistochemistry, confirming plasma protein extravasation
Postmortem studies: Reduced tight junction proteins, 20-30% pericyte loss, and basement membrane thickening

Mechanisms of BBB Breakdown in AD:

Aβ-mediated damage: [Amyloid-beta] oligomers directly damage endothelial cells, reduce claudin-5 and occludin expression, and activate inflammatory signaling via [RAGE](/proteins/rage)

Cerebral amyloid angiopathy (CAA): Aβ deposition in vessel walls (present in ~80% of AD brains) disrupts BBB structure, causes microhemorrhages, and impairs perivascular drainage

Pericyte degeneration: Accelerated pericyte loss increases non-selective transcytosis and reduces barrier function

APOE4-mediated dysfunction: [APOE4](https://doi.org/10.1038/nature11087) carriers show accelerated BBB breakdown via the CypA-MMP9 pathway[@bhatt2025c]

Increased permeability: Allows peripheral toxins into the brain
Impaired clearance: Reduced efflux of [amyloid-beta] from the brain [@bhatt2025d]### Cerebrovascular Amyloid Angiopathy (CAA)

Cerebrovascular amyloid angiopathy is characterized by Aβ deposition in the walls of cerebral blood vessels, affecting approximately 80% of AD patients to varying degrees[@kook2012]:

Pathological Features:

Vascular Aβ Deposition: Aβ accumulates in the media and adventitia of leptomeningeal and cortical vessels[@lue2001]

Microaneurysm Formation: Affected vessels develop microaneurysms prone to rupture[@origlia2008]

Relationship to BBB Breakdown:

CAA directly contributes to BBB dysfunction through:

Direct Endothelial Damage: Vascular Aβ causes endothelial cell dysfunction and death[@villarreal2021]
Pericyte Injury: CAA-associated pericyte degeneration further compromises barrier function[@deane2004]

The Two-Hit Vascular Hypothesis of AD

The two-hit vascular hypothesis proposes that vascular dysfunction (hit one) precedes and contributes to neurodegenerative changes (hit two) in AD[@shibata2000]:

Hit One: Vascular dysfunction

BBB breakdown allows peripheral Aβ and other toxins into the brain
Reduced cerebral blood flow leads to hypoxia and metabolic stress
Neurovascular uncoupling impairs activity-dependent blood flow responses

Hit Two: Neurodegeneration

Aβ accumulation in brain parenchyma and vessels
Tau pathology spread due to impaired clearance
Synaptic and neuronal loss due to combined vascular and toxic insults

Evidence Supporting the Hypothesis:

Vascular Risk Factors: Hypertension, diabetes, and cardiovascular disease increase AD risk[@fryer2005]

Neuroimaging Studies: BBB breakdown can be detected in cognitively normal individuals before clinical symptoms[@zlokovic2010]

Genetic Factors: Vascular risk genes (e.g., APOE4) modulate both vascular and AD pathology[@charidimou2012]

Parkinson's Disease

BBB breakdown in the [substantia nigra] and striatum correlates with dopaminergic neurodegeneration
[Alpha-synuclein] oligomers disrupt tight junction proteins via activation of metalloproteinases
Reduced P-glycoprotein expression may impair clearance of toxic dopamine metabolites
Neuromelanin-released iron from degenerating [neurons] damages nearby endothelial cells
BBB dysfunction may explain the selective vulnerability of the nigrostriatal pathway

Amyotrophic Lateral Sclerosis

Blood-spinal cord barrier (BSCB) breakdown is an early feature of [ALS], detected before symptom onset in animal models
Pericyte degeneration and endothelial damage in the spinal cord ventral horn
IgG, hemoglobin, and thrombin deposits found in ALS spinal cord tissue
May allow entry of neurotoxic factors that damage [motor neurons](/cell-types/motor-neurons)
[TDP-43] and BBB: Loss of nuclear [TDP-43] in endothelial cells disrupts tight junction pathways, activates [NF-κB] signaling, and reduces Wnt/β-catenin barrier maintenance — directly linking the hallmark proteinopathy of ALS/FTD to vascular dysfunction[@bhatt2025]. ALS-FTD mutations in [TDP-43] (e.g., TardbpG348C) cause cell-autonomous loss of junctional complexes, fibrin deposition, gliosis, and phospho-tau] accumulation[@bhatt2025a]

Huntington's Disease

BBB permeability is increased in the [striatum] and [cortex] of HD patients
Mutant [huntingtin] /proteins/huntingtin) expression in endothelial cells impairs tight junction integrity
Increased MMP activity degrades basement membrane components
Cerebral blood flow reductions precede neuronal loss

Multiple Sclerosis

BBB breakdown is a defining feature; enables autoreactive immune cell entry into the CNS
Gadolinium-enhancing lesions on MRI directly demonstrate active BBB leakage
Therapeutic targets: natalizumab (anti-α4 integrin VLA-4) prevents leukocyte crossing via VCAM-1; demonstrates BBB-targeted therapy can be clinically effective

BBB Imaging and Biomarkers

In Vivo BBB Assessment

| Method | What It Measures | Advantages | Limitations |
|--------|-----------------|------------|-------------|
| DCE-MRI (Ktrans) | Regional BBB permeability | Non-invasive; anatomical resolution | Requires specialized sequences; subtle leaks hard to detect |
| CSF/serum albumin ratio | Global BBB leakage | Simple; well-established | No anatomical localization |
| CSF sPDGFRβ | Pericyte injury | Specific to neurovascular unit | Requires lumbar puncture |
| Quantitative susceptibility mapping (QSM) | Regional iron accumulation | Non-invasive; links iron to BBB | Indirect measure |
| Arterial spin labeling (ASL) MRI | Cerebral blood flow | No contrast agent needed | Lower sensitivity |
| PET with 11Cverapamil | P-glycoprotein function | Specific efflux transporter assessment | Radiotracer availability |

Blood-Based Biomarkers

Emerging plasma markers of BBB integrity (no lumbar puncture required):

Plasma sPDGFRβ: Pericyte injury marker; elevated in AD and cognitive impairment[@french2025]
Plasma [NfL]: Neurofilament light chain partly reflects BBB dysfunction in addition to neuronal injury
Plasma [GFAP]: Elevated in AD partly due to reactive astrogliosis at the BBB
Extracellular vesicle (EV) cargo: BBB-derived EVs in blood carry tight junction proteins; altered in neurodegeneration

Diagnostic Biomarkers for BBB Dysfunction in AD

BBB dysfunction can be assessed through:

MRI Techniques: Dynamic contrast-enhanced MRI shows BBB leakage in AD patients[@attems2008]
CSF Biomarkers: Increased CSF/serum albumin ratio indicates BBB breakdown[@vinters1987]
P-gp Function: SPECT/PET tracers can assess P-gp activity as a marker of BBB function[@weller1998]

Therapeutic Strategies

BBB-Protective Therapeutics

Approaches to restore or protect BBB integrity:

Pericyte-supporting therapies: PDGF-BB supplementation promotes pericyte survival; CypA inhibitors (cyclosporine A analogs) block the CypA–MMP9 pathway specifically relevant in APOE4 carriers
Tight junction stabilizers: Compounds that upregulate claudin-5 and occludin expression; adeno-associated virus (AAV)-mediated claudin-5 restoration in preclinical models
Anti-inflammatory approaches: Reducing [neuroinflammation]-mediated BBB damage; anti-TNF and anti-IL-1β strategies
Wnt/β-catenin activation: Restoring canonical Wnt signaling promotes BBB differentiation and tight junction expression; particularly relevant given [TDP-43]-mediated Wnt pathway disruption in ALS/FTD
[RAGE](/proteins/rage) antagonists / [LRP1] agonists: Shifting the [RAGE](/proteins/rage)-[LRP1] balance toward net Aβ clearance

Therapeutic Targets in AD

Understanding BBB dysfunction has led to several therapeutic approaches:

RAGE Inhibitors: Small molecule inhibitors (e.g., FPS-ZM1) block RAGE-Aβ interaction[@paris2003]

LRP1 Enhancers: Strategies to upregulate LRP1 expression for improved Aβ clearance[@halliday2016]

Pericyte Protection: PDGFR-β agonists and pericyte survival factors[@greenberg2009]

Tight Junction Stabilizers: MMP inhibitors and anti-inflammatory agents[@zlokovic2008]

BBB-Crossing Drug Delivery

Overcoming the BBB for CNS drug delivery remains one of the greatest challenges in neuroscience therapeutics:

Bispecific antibody shuttles: Engineered antibodies that bind transferrin receptor (TfR1) on one arm and a therapeutic target on the other, leveraging RMT to cross the BBB. Roche's "Brain Shuttle" platform and Denali's "Transport Vehicle" (TV) technology are in clinical development[@bhatt2025b]
Focused ultrasound (FUS): Microbubble-mediated transient BBB opening for drug delivery; in Phase I/II clinical trials for AD ([lecanemab] + FUS, anti-tau] antibody + FUS). Allows targeted, reversible BBB opening in specific brain regions
Nanoparticles: Ligand-decorated polymeric and lipid nanoparticles leveraging RMT for brain delivery; ZnO quantum dot-based gene delivery systems show preclinical promise for crossing the BBB and providing neuroprotection
[LRP1]-targeted polymersomes: Multivalent [LRP1] engagement promotes transcytosis and upregulates LRP1 expression; reduced brain Aβ by ~45% in AD mice
Intranasal delivery: Bypasses BBB via olfactory and trigeminal nerve pathways; used for insulin (Phase II/III for AD), oxytocin, and neurotrophic factor delivery
mRNA lipid nanoparticles: Building on COVID-19 vaccine technology; engineered for brain-targeted delivery of therapeutic mRNA; early preclinical data show promise
J-Brain Cargo technology: Developed by JCR Pharmaceuticals; uses TfR-mediated transcytosis for delivering enzymes, antibodies, and AAV gene therapies across the BBB; in clinical development for lysosomal storage disorders

BBB-on-a-Chip Models

Advances in microphysiological systems are improving BBB research:

Human iPSC-derived BBB-on-chip models that recapitulate tight junctions, efflux transporters, and immune cell trafficking
Enable patient-specific (e.g., APOE4 carrier) BBB modeling and drug screening
Humanized mouse models with human BBB components improve translational predictability for CNS drug candidates

Conclusion

Blood-brain barrier breakdown in [Alzheimer's disease](/diseases/alzheimers-disease) represents a fundamental pathological process that contributes to disease initiation and progression. The interconnected mechanisms—pericyte degeneration, tight junction disruption, altered Aβ transport via RAGE/LRP1, and cerebrovascular amyloid angiopathy—create a self-perpetuating cycle of vascular and neuronal dysfunction. These mechanisms are also relevant to [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Huntington's disease](/diseases/huntingtons), and [multiple sclerosis](/diseases/multiple-sclerosis), where BBB dysfunction plays a role in disease progression. Understanding these mechanisms provides critical insights for developing diagnostic biomarkers and therapeutic interventions targeting the neurovascular unit in neurodegenerative disorders.

External Links

[Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data
[PubMed: Blood-Brain Barrier](https://pubmed.ncbi.nlm.nih.gov/?term=blood+brain+barrier+neurodegeneration)
[KEGG: Tight Junction Pathway](https://www.kegg.jp/pathway/hsa04530)

Background

The study of Blood Brain Barrier has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Structure and Components

The blood-brain barrier is not a single anatomical entity but rather a complex interface composed of multiple cell types working in concert:

Endothelial Cells

The cerebral endothelial cells form the primary structural component of the BBB. Unlike peripheral endothelium, brain endothelial cells exhibit unique characteristics:

Tight Junctions: Specialized cell-cell adhesion complexes that create a nearly continuous seal between adjacent endothelial cells, limiting paracellular diffusion [@sweeney2018]
Reduced Pinocytosis: Minimal caveolae and transcytotic vesicles that limit transcellular transport [@armulik2010]
High Mitochondrial Content: Reflecting high metabolic demand for active transport processes [@montagne2015]

Tight Junction Proteins

The integrity of the BBB depends on specialized tight junction proteins:

| Protein | Function |
|---------|----------|
| Claudin-5 | Primary seal-forming claudin in brain endothelial cells [@nation2019] |
| Occludin | Structural protein involved in tight junction assembly [@bell] |
| ZO-1, ZO-2, ZO-3 | Scaffolding proteins linking junctional proteins to actin cytoskeleton [@bhatt2025] |

The Neurovascular Unit

The BBB functions as part of the neurovascular unit, which includes:

Endothelial Cells: The barrier-forming component

[Pericytes]: Perivascular cells that regulate capillary blood flow and BBB development/maintenance [@bhatt2025a]

[Astrocytes]: Astrocyte end-feet ensheath cerebral vessels and release factors that maintain BBB integrity [@french2025]

[Neurons]: Coordinate neurovascular coupling to match blood flow to neural activity [@bhatt2025b]

Basement Membrane: Extracellular matrix layer providing structural support [@zlokovic2011]

Protection

Exclusion of pathogens: Prevents bacteria, viruses, and toxins from entering the brain
Removal of toxins: Efflux transporters pump harmful substances back into the bloodstream
Immune privilege maintenance: Limits immune cell entry under normal conditions [@daneman2015]

Homeostasis

Ion gradient maintenance: Ensures optimal ion concentrations for neuronal function
Nutrient transport: Provides receptor-mediated uptake of essential nutrients (glucose, amino acids)
Waste clearance: Facilitates removal of metabolic byproducts from the brain [@profaci2020]

Selective Transport

The BBB allows passage of:

Small lipophilic molecules: Via passive diffusion
Essential nutrients: Via specific transporters (GLUT1 for glucose)
Therapeutic drugs: Often limited due to BBB impermeability
CNS-specific proteins: Via receptor-mediated transcytosis [@knox2022]

Other Neurological Disorders

BBB dysfunction is implicated in:

Multiple Sclerosis: Immune cell infiltration across the BBB [@abbott2010]
Stroke: Ischemia-induced BBB breakdown [@verbeek1997]
Epilepsy: Seizure-induced BBB disruption [@sengillo2013]
Parkinson Disease: Regional BBB leakage in substantia nigra [@routhe2022]

Drug Delivery Challenges

The BBB poses a significant challenge for central nervous system drug delivery. Strategies being explored include:

Nanoparticle delivery: Using lipid or polymer nanoparticles to ferry drugs across [@takano2007]

Transient BBB opening: Using focused ultrasound or hyperosmolar agents [@liu2012]

Inhibiting efflux pumps: Blocking P-glycoprotein to enhance drug accumulation [@romanitan2010]

Biomarkers

BBB dysfunction can be assessed through:

Neuroimaging: Dynamic contrast-enhanced MRI [@harris2021]
Cerebrospinal fluid analysis: Albumin quotient [@pun2009]
Endothelial biomarkers: Soluble adhesion molecules in blood [@de1996]

Imported Legacy Notes

Blood-Brain Barrier

The blood-brain barrier (BBB) is a highly specialized interface that separates the circulating blood from the brain and extracellular fluid in the central nervous system. This dynamic structure maintains brain homeostasis by tightly regulating the passage of ions, molecules, and cells between the bloodstream and the brain parenchyma.

References

[Sweeney MD, et al., Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133-150. [DOI (2018)](https://doi.org/10.1038/nrn.2018.16)

[Armulik A, et al., Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323:557-561. [DOI (2010)](https://doi.org/10.1038/nature09522)

[DOI:10.1016/j.neuron.2014.12.032](https://doi.org/10.1016/j.neuron.2014.12.032)

[Nation DA, et al., Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270-276. [DOI (2019)](https://doi.org/10.1038/s41591-018-0297-y)

[Bell RD, et al., [Apolipoprotein E( (n.d.)](https://doi.org/10.1038/nature11087)

[Bhatt M, et al, Endothelial [TDP-43] depletion disrupts core blood-brain barrier pathways in neurodegeneration (2025)

[Bhatt M, et al, ALS and FTD mutation reduces endothelial [TDP-43] and causes blood-brain barrier defects (2025)

[French L, et al., Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia. Alzheimers Dement. 2025;21(3):e70104. [DOI (2025)](https://doi.org/10.1002/alz.70104)

Bhatt K, et al., Strategies for delivering drugs across the blood-brain barrier for neurodegenerative diseases. Front Drug Deliv. 2025;5:1644633. [DOI: 10.3389/fddev.2025.1644633 (2025)

[Unknown, Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-738. [DOI (2011)](https://doi.org/10.1038/nrn3114)

[Unknown, Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1:a020412. [DOI (2015)](https://doi.org/10.1101/cshperspect.a020412)

[Profaci CP, et al., The blood-brain barrier in health and disease: important unanswered questions. J Exp Med. 2020;217(4):e20190062. [DOI (2020)](https://doi.org/10.1084/jem.20190062)

Knox EG, et al., The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry. 2022;27(6:2659-2673. [DOI: 10.1038/s41380-022-01511-z) (2022)

[Langen UH, et al., Development and cell biology of the blood-brain barrier. Annu Rev Cell Dev Biol. 2019;35:591-613. [DOI (2019)](https://doi.org/10.1146/annurev-cellbio-100617-062608)

Bhatt S, et al., Overcoming the blood-brain barrier: advanced strategies in targeted drug delivery for neurodegenerative diseases. Pharmaceutics. 2025;17(8):1041. [PMC (2025)

Bhatt K, et al., The crucial role of the blood-brain barrier in neurodegenerative diseases: mechanisms of disruption and therapeutic implications. J Clin Med. 2025;14(2):386. [DOI: 10.3390/jcm14020386 (2025)

[Abbott NJ, et al., Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1:13-25. [DOI (2010)](https://doi.org/10.1016/j.nbd.2009.07.030)

[Verbeek MM, et al., Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J Neurochem. 1997;68(3):1135-1141. [DOI (1997)](https://doi.org/10.1046/j.1471-4159.1997.68031135.x)

[Sengillo JD, et al., Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol. 2013;23(3):303-310. [DOI (2013)](https://doi.org/10.1111/bpa.12004)

[Routhe LJ, et al., Pericyte dysfunction and reduced pericyte coverage in an in vitro model of the blood-brain barrier in Alzheimer's disease. Cell Mol Neurobiol. 2022;42(7):2297-2314. [DOI (2022)](https://doi.org/10.1007/s10571-021-01124-4)

[Daneman R, et al., Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468(7323):562-566. [DOI (2010)](https://doi.org/10.1083/jcb.201002051)

Takano T, et al, Two-photon imaging of blood flow in brain capillaries and arterioles in [APP]/PS1 mice (2007)

[Liu J, et al., Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier breakdown in hyperosmolarity. J Neurophysiol. 2012;107(2):782-792. [DOI (2012)](https://doi.org/10.1152/jn.00692.2011)

[Romanitan MO, et al., Altered expression of claudin-5, claudin-7, and occludin in the blood-brain barrier in Alzheimer's disease. J Cell Mol Med. 2010;14(5):1088-1100. [DOI (2010)](https://doi.org/10.1111/j.1582-4934.2009.00981.x)

[Harris JI, et al., Zonula occludens-1 and -2 expression in human brain tissue and relevance to Alzheimer's disease. J Alzheimers Dis. 2021;82(4):1487-1498. [DOI (2021)](https://doi.org/10.3233/JAD-210234)

[DOI:10.1080/10715760902751974](https://doi.org/10.1080/10715760902751974)

[de Vries HE, et al., The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996;64(1):37-43. [DOI (1996)](https://doi.org/10.1016/0165-5728(95)

[Rempe RG, et al., Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36(9):1481-1507. [DOI (2016)](https://doi.org/10.1177/0271678X16655551)

[Kook SY, et al., Aβ-induced disruption of the blood-brain barrier via TRPV4 activation of endothelial cells. Neurobiol Aging. 2012;33(5):e17-e28. [DOI (2012)](https://doi.org/10.1016/j.neurobiolaging.2011.12.036)

[Yan SD, et al., RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382(6593):685-691. [DOI (1996)](https://doi.org/10.1038/382685a0)

[Lue LF, et al., Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism. Exp Neurol. 2001;171(1):29-45. [DOI (2001)](https://doi.org/10.1006/exnr.2001.7737)

[Origlia N, et al., MAPK-dependent RAGE signaling is involved in AGEs-induced neuronal dysfunction. Mol Cell Neurosci. 2008;37(3):520-527. [DOI (2008)](https://doi.org/10.1016/j.mcn.2007.12.001)

[Villarreal A, et al., Activation of RAGE induces BBB disruption and neuronal death. Cell Mol Neurobiol. 2021;41(7:1515-1531. [DOI (2021)](https://doi.org/10.1007/s10571-020-00970-w)

[Kanekiyo T, et al., LRP1 and apoE at the blood-brain barrier. Nat Rev Neurosci. 2014;15(12:819-830. [DOI (2014)](https://doi.org/10.1038/nrn3820)

[Deane R, et al., LRP1 clears Aβ. Dev Cell. 2004;6(6:829-837. [DOI (2004)](https://doi.org/10.1016/j.devcel.2004.05.002)

[Shibata M, et al., LRP1 in brain homeostasis. J Clin Invest. 2000;106(12:1489-1499. [DOI (2000)](https://doi.org/10.1172/JCI10498)

[Fryer JD, et al., Human apoE4-targeted replacement mice. J Neurosci. 2005;25(11:2803-2810. [DOI (2005)](https://doi.org/10.1523/JNEUROSCI.5180-04.2005)

[Zlokovic BV, et al., Low-density lipoprotein receptor-related protein-1: A serial clearance gateway for Aβ. Neurobiol Aging. 2010;31(12):2147-2158. [DOI (2010)](https://doi.org/10.1016/j.neurobiolaging.2010.04.030)

[Charidimou A, et al., Sporadic cerebral amyloid angiopathy revisited: Recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012;83(2):124-137. [DOI (2012)](https://doi.org/10.1136/jnnp-2011-301308)

[Attems J, et al., The overlap between vascular and neurodegenerative pathologies in AD. Neurology. 2008;71(14:1077-1084. [DOI (2008)](https://doi.org/10.1212/01.wnl.0000228230.69645.f3)

[Unknown, Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18(2:311-324. [DOI (1987)](https://doi.org/10.1161/01.STR.18.2.311)

[Weller RO, et al., Cerebral amyloid angiopathy: Amyloid angiopathy in AD. Acta Neuropathol. 1998;96(1:50-57. [DOI (1998)](https://doi.org/10.1007/s004010050862)

[Paris D, et al., Vessels are a source of Aβ. Neurobiol Aging. 2003;24(7:1073-1077. [DOI (2003)](https://doi.org/10.1016/S0197-4580(03)

[Halliday MR, et al., Pericyte degeneration in CAA. Nat Med. 2016;22(11:1199-1205. [DOI (2016)](https://doi.org/10.1038/nm.4197)

[Greenberg SM, et al., Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol. 2009;8(2:165-174. [DOI (2009)](https://doi.org/10.1016/S1474-4422(09)

[Unknown, Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2:178-201. [DOI (2008)](https://doi.org/10.1016/j.neuron.2008.01.003)

[Montagne A, et al., Blood-brain barrier breakdown in aging and AD. Neuron. 2015;85(3:462-478. [DOI (2015)](https://doi.org/10.1016/j.neuron.2015.01.017)

[DOI:10.1038/nrneurol.2012.263](https://doi.org/10.1038/nrneurol.2012.263)

[Starr JM, et al., Blood-brain barrier permeability in Alzheimer's disease: A case-control MRI study. Psychiatry Res. 2009;171(3):232-241. [DOI (2009)](https://doi.org/10.1016/j.pscychresns.2008.04.015)

[Skillbäck T, et al., CSF/serum albumin ratio in dementia. Neurology. 2015;84(6:620-627. [DOI (2015)](https://doi.org/10.1212/WNL.0000000000001319)

[van Assema DM, et al., P-gp function in AD. Brain. 2012;135(1:181-189. [DOI (2012)](https://doi.org/10.1093/brain/awr298)

[Deane R, et al., A critical role for RAGE. J Clin Invest. 2012;122(4:1377-1392. [DOI (2012)](https://doi.org/10.1172/JCI61598)

[Bachmeier C, et al., LRP1 upregulation. J Alzheimers Dis. 2013;37(2:343-352. [DOI (2013)](https://doi.org/10.3233/JAD-130182)

[Nikolakopoulou AM, et al., PDGFRβ pericyte restoration. Acta Neuropathol. 2019;138(4:539-556. [DOI (2019)](https://doi.org/10.1007/s00401-019-02029-5)

[Yang Y, et al., MMP-mediated blood-brain barrier dysfunction in AD. ASN Neuro. 2015;7(4:1759091415592115. [DOI (2015)](https://doi.org/10.1177/1759091415592115)

Pathway Diagram

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

entities-blood-brain-barrier

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-blood-brain-barrier
kg_node_id	None
entity_type	general
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5743c0db0e19
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-blood-brain-barrier'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

200

Outgoing

226

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

blood-brain-barrier

blood-brain-barrier

Blood-Brain Barrier

Introduction

Overview

blood-brain-barrier

Blood-Brain Barrier

Introduction

Overview

Structure of the Neurovascular Unit

Brain Endothelial Cells

Pericytes

Astrocytic End-Feet

Basement Membrane

BBB Transport Mechanisms

Paracellular Pathway

Transcellular Pathways

RAGE and LRP1: The Aβ Transport Dance

Age-Related Transcytosis Shift

The Two-Hit Vascular Hypothesis of AD

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Multiple Sclerosis

BBB Imaging and Biomarkers

In Vivo BBB Assessment

Blood-Based Biomarkers

Diagnostic Biomarkers for BBB Dysfunction in AD

Therapeutic Strategies

BBB-Protective Therapeutics

Therapeutic Targets in AD

BBB-Crossing Drug Delivery

BBB-on-a-Chip Models

Conclusion

External Links

See Also

Background

Structure and Components

Endothelial Cells

Tight Junction Proteins

The Neurovascular Unit

Protection

Homeostasis

Selective Transport

Other Neurological Disorders

Drug Delivery Challenges

Biomarkers

Imported Legacy Notes

Blood-Brain Barrier

References

Pathway Diagram

💬 Discussion